Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it publishes its initial advice on the medications.
Considering over a billion people worldwide currently obese, it is urging more widespread and fairer access to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with holistic and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to widespread access to the treatments that can assist patients in reducing considerable body mass, explains the organization.
Even in the present most optimistic outlook, the supply of these medications would only suffice for approximately 100 million people – under 10% of the global need, per the health organization.
The recommendation urges countries and companies to increase access, by measures like licensing agreements.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
These medications mimick a biological compound to slow digestion, curb appetite and enhance the sense of being full so people consume fewer calories.
Patients usually begin shedding pounds after several weeks of starting on the once-weekly jabs.
Research indicates patients may put most of the weight back on after a year of stopping the treatment, as their normal food cravings return.
Being above a healthy weight increases your risk for contracting diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
Elena Voss is a seasoned journalist and editor with over a decade of experience in digital media, specializing in global affairs and tech trends.